GlassScriptPhysician profile
Glen M Arluk
NPI 1861462913
$8,507.42
in general payments reported to CMS, 2019-2025
38 companies · $1,465 in 2025
The $1,465 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $316 · 2021: $307 · 2022: $2,231 · 2023: $1,547 · 2024: $2,150 · 2025: $1,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,634 · Consulting Fee: $425 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,634.15 |
| Consulting Fee | $425.00 |
| Education | $103.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,851.02 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Medtronic, INC. | $1,562.03 | 2022-2025 | Pillcam, Gi Genius, Interstim |
| Boston Scientific Corporation | $794.17 | 2022-2025 | Orcapod, Exalt Model D |
| Janssen Biotech, INC. | $514.27 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $502.75 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $301.19 | 2022-2024 | Dupixent |
| Pfizer INC. | $248.35 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.14 | 2022-2025 | Xifaxan |
| Ardelyx, INC. | $213.64 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $213.41 | 2024 | |
| Celgene Corporation | $206.23 | 2022-2024 | Zeposia |
| Covidien LP | $164.56 | 2019 | |
| Lilly USA, LLC | $139.58 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $132.51 | 2019-2025 | Injectafer |
| Ferring Pharmaceuticals INC. | $125.81 | 2022-2024 | Rebyota |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $118.38 | 2024-2025 | Zymfentra, Vegzelma |
| Ambu INC. | $108.45 | 2020 | |
| Intercept Pharmaceuticals, INC. | $106.78 | 2019-2025 | Ocaliva |
| Olympus America INC. | $97.97 | 2023-2025 | Visiglide |
| Alnylam Pharmaceuticals INC. | $90.43 | 2024-2025 | Givlaari |
| Qol Medical, LLC | $88.68 | 2024-2025 | Sucraid, Sucraid |
| E.R. Squibb & Sons, L.L.C. | $86.03 | 2021 | |
| Nestle Healthcare Nutrition INC. | $81.46 | 2021-2023 | |
| Tersera Therapeutics LLC | $67.16 | 2023 | Xermelo |
| Ironwood Pharmaceuticals, INC | $58.61 | 2019-2024 | |
| Braintree Laboratories, INC. | $52.33 | 2023-2025 | Sutab, Suflave |
| Amgen INC. | $46.63 | 2022-2023 | Avsola, Amjevita |
| Novo Nordisk INC | $42.84 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $40.52 | 2024-2025 | Iqirvo |
| Sandoz INC. | $39.26 | 2025 | Hyrimoz |
| Aimmune Therapeutics, INC. | $28.04 | 2024 | |
| W. L. Gore & Associates, INC. | $27.67 | 2021-2023 | Gore Cardioform Septal Occluder |
| Alfasigma USA, INC. | $27.55 | 2020 | |
| Allergan, INC. | $23.26 | 2019-2020 | |
| Redhill Biopharma INC. | $17.45 | 2020 | |
| Madrigal Pharmaceuticals | $17.20 | 2025 | Rezdiffra |
| Organon LLC | $15.62 | 2023 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.44 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Arluk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.